|
Network with Numerous Investment Leaders, Emerging Medtech Innovators, Manufacturing Companies, Patent & Copyright LLCs, Regulatory Officials, and Other Noteworthy Service Providers that Enable the Medtech Investment World to Grow and Prosper.
IN3 (“investment in innovation”) and guests were so pleased with the success of our new conference format at IN3 Summit, that we are happy to announce IN3 East will also integrate Investor Day with the main program, for a full, two (3) days of start-up presentations, investor presentations, and key plenary/panel sessions.
Alandra Medical, Inc.
Alandra Medical is at the forefront of the medtech innovation offshoring trend in offering capital efficient design, deveopment and clinical trial services. They also invest services-for-equity.
-
Apeliotus Vision Science
Apeliotus is commercializing a simple diagnostic for early detection of a blinding eye disease called age-related macular degeneration (AMD), allowing intervention before the onset of significant vision loss.
-
Audax Medical
Our revolutionary approach to fracture repair works with the body to remodel and reestablish function in a patient's vertebra. Our products go beyond simply stabilizing a clinical deficiency by promoting the growth of natural bone and tissue.
-
Bone Biologics, Inc.
Bone Biologics is an orthobiologics company with a patented platform technology, UCB-1, a recombinant protein that regenerates bone and tissue.
-
BovedaMarco Inc.
A multi-array catheter system to treat in a single setting patients presenting persistent/chronic atrial fibrillation allowing pulmonary vein ablation and left segmentation.
-
BrainScope Company, Inc.
The BrainScope Company, Inc. is developing a radically new generation of hand-held devices that operate as digital translators of the electrical activity of the brain - timely, mobile and out-at-edge.
-
Cequr Ltd.
CeQur's lead product candidate is a small, wearable insulin delivery device that delivers both basal and bolus doses subcutaneously. Its simple and discrete design enables patients to more easily comply with insulin regimens and experience the benefits of intensive insulin therapy.
-
CerviLenz
CerviLenz® is an innovative medical device that helps identify pregnant women at high risk for preterm birth and influence treatment.
-
CSA Medical Inc.
Novel, Patented, FDA Cleared, Energy Based Medical System: Spray Cryotherapy.
-
Dialog Devices, Ltd.
Dialog Devices presents Padd for peripheral arterial disease assessment in Primary Care to prevent heart disease and stroke.
-
Enox BioPharma
Enox Biopharma utilizes Nitric Oxide (NO) as an antimicrobial agent. NO is an ideal antimicrobial as it is highly effective, broad spectrum and does not have issues of antibiotic resistance. It can be dosed into medical devices after they have been manufactured and sterilized.
-
Fibralign Corporation
High value implantable products created from proprietary fibrillar biopolymers (collagen, laminin, others) as well as supply these biopolymers to third parties and researchers.
-
Glysure
Continuous glucose monitoring system using an intravascular, optical fluorescence-based sensor to support clinical implementation of Tight Glycemic Control and Intensive Insulin Therapy.
-
Health-Chem Diagnostics
Non Invasive Blood Glucose System for Diabetic Self Testing.
-
Histogenics Corporation
Leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. The company’s flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility.
-
Intellectual Ventures
The inventor teams at Intellectual Ventures have worked diligently for the better part of a decade developing ideas and inventions relating to medical devices, diagnostic tools and advancements for the life sciences.
-
Intrinsic Therapeutics, Inc.
Intrinsic's Barricaid Prosthesis provides the added security of bone-anchored reconstruction that can be used to reconstruct larger regions of the anulus or in cases where anular integrity is in question.
-
Kerecis Limited
Novel tissue regeneration product for chronic wounds and hernia repair. Its patent pending fish skin derived material improves upon current human and porcine technologies through improved economics and clinical performance, reduced disease transfer risk and absence of cultural constraints on usage.
-
LKC Technologies
LKC Technologies is developing a breakthrough device to screen diabetics for diabetic retinopathy at the point of care. This device will allow a diabetic to be tested in their GP, Internist, Endocrinologist, or clinic in less than five minutes.
-
LumiNIR LLC
LumiNIR has developed a noninvasive, optical brain monitor for monitoring depth of anesthesia and level of sedation via direct measurement of deoxyhemoglobin and hemodynamic response.
-
Marvao Medical
Marvao Medical's NexSite CVC aims to significantly reduce infections, reduce hospital costs, extend vascular access longevity, and simplify patient care. NexSite technology enables a patient’s skin to fully heal into the catheter at its exit site, blocking this potential route for infection.
-
MC10, Inc.
mc10 develops and promotes a new generation of thin, conformal electronics technology that endures bending, twisting, and stretching without sacrificing performance.
-
Neurowave Systems, Inc.
NeuroWave is proud to offer the NeuroSENSE® Monitor, the latest generation of brain monitors for patient-customized anesthesia and sedation, now cleared for sale in markets recognizing the CE mark.
-
Nuubo
Nuubo improves the lives of cardiac patients via a next-generation wireless remote monitoring platform. The solution is a proprietary, non-invasive and multi-leaded ECG system based on biomedical e-textile technology.
-
PCAsso Diagnostics LLC
PCAsso Diagnostics LLC is a New Jersey start-up diagnostics company developing PolyChromatic Angiography (PCA), the next generation quantitative retinal angiography.
-
Premia Spine
Premia Spine is commercializing the TOPS™ System, an alternative to traditional fusion surgery for patients suffering from moderate to severe lumbar spinal stenosis.
-
Soft Tissue Regeneration, Inc.
Soft Tissue Regeneration, Inc. has developed a biocompatible and biodegradable scaffold to regenerate the anterior cruciate ligament ("ACL") of the knee.
-
Synthasome, Inc.
Synthasome is an emerging orthopaedic company developing and marketing innovative products for tendon, ligament and cartilage repair and regeneration.
-
ThermopeutiX, Inc.
Developed a family of Cooltools™ that address the next frontiers in interventional medicine. The product line includes support/microcatheters and drug delivery systems to advance the treatment of vascular-related disorders, and a novel catheter system and technique for the treatment of ischemic brain injury (e.g., stroke, cardiac arrest, trauma).
-
IN3 East 2011
Brochure Download
Get event information in a convenient PDF format.
-
IN3 Summit 2010
Audio Session
Listen to key plenary session topics.
-
IN3 West 2011
Brochure Download
Get event information in a convenient PDF format.
-
IN3 Summit 2010
Brochure Download
Get event information in a convenient PDF format.
-
IN3 East 2010
Proceedings Book
Get event information in a convenient PDF format.
-
Free Article
IN VIVO - July 2010
"Device VCs Find New Hope in Old Exit Path"
-
Free Article
Start-Up - July 2010
"As Some VCs Run On Empty, Others Are Topping Off The Tank"
-
IN3 West 2010
Proceedings Book
Get event information in a convenient PDF format.
-
IN3 West 2010
Audio Session
Listen to key plenary session topics.
-
IN3 West 2010
Session Slides
View Investor Day VC presentations.
-
IN3 Europe 2009
Audio Session
Listen to key plenary session topics.
-
IN3 Summit 2009
Audio Session
Listen to key plenary session topics.
-
IN3 Europe Video
Get 'behind the scenes' info on this event.
-
IN3 East Video
Get 'behind the scenes' info on this event.
-
October 26-28, 2011
San Francisco, CA - USA
-
.jpg)
Spring, 2012
Las Vegas, NV - USA
Medtech innovator presentations are now mixed within the same time block as VCs, allowing emerging companies to get in front of more potential investment suitors. Plus, we’ve added more plenary/panel sessions to benefit the needs of all audience members, including special lunch and reception sessions from our key sponsors. And as always, you’ll hear top industry leaders speak about regulatory issues, hot investment areas, real life case studies on investing and M&A, philosophy to investments, and more.
And as always, IN3 conferences specifically partner a global audience of VCs, top investors, and corporate acquirers with early-/mid-/late-stage, medical technology start-ups and revolutionary innovators.
In the modern economy, medtech start-ups face intense competition for a finite amount of available capital funding. This makes IN3 events the ideal setting for emerging companies to meet and impress potential investors from many of the top-tier device companies and discerning healthcare investment firms from around the world.
| IN3 East is a must-attend event if you are… |
- • An emerging company interested in what investment leaders in the industry are thinking, doing, and planning. Top-tier venture capitalists and corporate acquirers address what interests them most in innovative technologies, therapeutic areas, products, and geographic markets. They will also discuss partnering opportunities, case studies, how to maximize visibility in front of large company investors, and the role of M&A.
- • A business development or financial community leader interested in investment, partnering, or acquisition opportunities with cutting-edge medtech innovators.
- • A service provider or industry affiliate who is seeking to meet and support innovators and market leaders with their business needs.
In between presentation blocks, benefit from dedicated, 30-minute, break-out sessions for coffee socials, one-on-one private meetings, use of Windhover’s special partnering software, or network throughout the duration of the event.
|
IN3 Summit 2010 Testimonials
"The IN3 Medical Device Summit gave me a chance to meet one-on-one with potential corporate partners as well as several other high-quality investors, which to me represents exceptional value,” said John Kraczkowsky, President and CEO of KCBioMedix®.
"The IN3 investor conferences deliver a first-class congress at which investors can productively identify advanced medical technologies at various stages of their development," said Jeani Delagardelle, a Managing Partner and leader of the medical device practice at New Leaf Venture Partners, a leading healthcare technology investor with more than $1 billion in funds under management.
"We are a repeat sponsor of Elsevier investor conferences," added Ann Gaddy, Managing Director, Life Science Angels. "The superior quality of the presenting companies makes IN3 the perfect venue in which to discover potentially blockbuster medical technology. It’s also a superbly managed gathering of buyers and sellers of medical technology."
Over 1,500 emerging medical technology company presenters and more than 8,000 attendees have participated at IN3 events over the past ten years. We are very proud to say that many young companies have worked their way up the funding ladder and into the marketplace via the relationships they formed at IN3 events. Click Here for success stories and testimonials from our past presenters and attendees.
For more information, please contact:
Kristy Kennedy at +1-480-985-9512 or Kayleen Kell at +1-855-202-5939 (USA only), or email IN3@Elsevier.com.
Best experienced using Internet Explorer 7+
Important Deadlines |
Save $100 before: |
05/31/2011 |
| Last Chance for Discounted Rooms (may sell out earlier) |
06/06/2011 |
| Partnering Opens (start scheduling meetings) |
06/08/2011 |
| Innovator Company Profile Due |
06/06/2011 |
Click Here to view full pricing schedule.
Who Attends
- • Presidents, Principals, CEOs, CTOs, COOs, CMOs
- • Founders, Board Leaders, Chairpersons
- • Venture Partners, Senior Investors, Private Equity, Angel Investors
- • VPs/Directors of Strategic Planning, Business Development/Analysis, Marketing, New Technology, Acquisitions, R&D, Sales
- • Established, large device companies seeking technology via licensing, partnering, and acquisition to broaden or deepen product lines or build sector strength.
- • VCs, private equity, investment firms/consultant, and investment banks.
- • Medical device, biopharmaceutical, biotech, or other company executives seeking investments or partnerships.
Benefits of Attending
- • More than 40 medical technology innovators give 10-minute presentations on their latest innovations within a wide range of high-growth markets.
- • Nearly 15 finance presentations and perspectives by some of the industry's biggest players.
- • Over two dozen networking opportunities without schedule overlap or program interrupt.
- • Partnering Software to identify attendees and plan private, one-on-one meetings in advance.
Learn more about the tremendous benefits!
- • Keynote sessions on the latest 'deals' case studies, device investing, M&A, health reform, clinicians, and more!
- • Cutting-edge news on investing and partnering, as driven by Elsevier Business Intelligence analysts.
About Partnering
Why Use Windhover Conferences Partnering Software?
- • Identify attendees to choose potential partners.
- • Search database of partnering/investing opportunities (including deal history and related articles).
- • Communicate and pre-schedule as many meetings as you wish with fellow attendees.
- • Showcase your company's innovative technology and investment/partnering interests.
More Info >>
Advisory Board
- Annette Campbell-White
Senior Managing Member
MedVenture Associates
- Michael Carusi
General Partner
Advanced Technology Ventures
- Luke Evnin
General Partner
MPM Capital
- Richard M. Ferrari
Managing Director
DeNovo Ventures
- William T. Harrington
Partner
Three Arch Partners
- Ross A. Jaffe
Managing Director
Versant Ventures
- Josh Makower
Venture Partner
NEA
- John Maroney
General Partner
Delphi Ventures
- Allan May
Chairman, Founder
Life Science Angels
Managing Director
Emergent Medical Partner
- David Milne
Managing Partner
SV Life Science Advisers
- Jesse I Treu
Partner
Domain Associates
|
|